# ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

> **NCT02100007** · PHASE1,PHASE2 · TERMINATED · sponsor: **MEI Pharma, Inc.** · enrollment: 46 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** ME-344
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT02100007
- **Lead sponsor:** MEI Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2016-01
- **Final completion:** 2016-04
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** lack of efficacy
- **Last updated:** 2017-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02100007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02100007, "ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT02100007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*